These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 32506752)

  • 1. CRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedside.
    Humbert O; Samuelson C; Kiem HP
    Br J Haematol; 2021 Jan; 192(1):33-49. PubMed ID: 32506752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
    Jensen TI; Axelgaard E; Bak RO
    Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
    Sarkar E; Khan A
    Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR to fix bad blood: a new tool in basic and clinical hematology.
    González-Romero E; Martínez-Valiente C; García-Ruiz C; Vázquez-Manrique RP; Cervera J; Sanjuan-Pla A
    Haematologica; 2019 May; 104(5):881-893. PubMed ID: 30923099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 genome engineering in hematopoietic cells.
    Sürün D; von Melchner H; Schnütgen F
    Drug Discov Today Technol; 2018 Aug; 28():33-39. PubMed ID: 30205879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 Gene Editing: From Basic Mechanisms to Improved Strategies for Enhanced Genome Engineering In Vivo.
    Salsman J; Masson JY; Orthwein A; Dellaire G
    Curr Gene Ther; 2017; 17(4):263-274. PubMed ID: 29173169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing.
    Iqbal Z; Rehman K; Xia J; Shabbir M; Zaman M; Liang Y; Duan L
    Biomater Sci; 2023 May; 11(11):3762-3783. PubMed ID: 37102700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
    Zhang X; Wang L; Liu M; Li D
    Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-based precision medicine for hematologic disorders: Advancements, challenges, and prospects.
    Sahu S; Poplawska M; Lim SH; Dutta D
    Life Sci; 2023 Nov; 333():122165. PubMed ID: 37832631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Application of CRISPR/Cas9 for the Treatment of Retinal Diseases.
    Peddle CF; MacLaren RE
    Yale J Biol Med; 2017 Dec; 90(4):533-541. PubMed ID: 29259519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9, the Powerful New Genome-Editing Tool for Putative Therapeutics in Obesity.
    Franco-Tormo MJ; Salas-Crisostomo M; Rocha NB; Budde H; Machado S; Murillo-Rodríguez E
    J Mol Neurosci; 2018 May; 65(1):10-16. PubMed ID: 29732484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalised genome editing - The future for corneal dystrophies.
    Moore CBT; Christie KA; Marshall J; Nesbit MA
    Prog Retin Eye Res; 2018 Jul; 65():147-165. PubMed ID: 29378321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
    Liu C; Zhang L; Liu H; Cheng K
    J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders.
    Wan T; Ping Y
    Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome editing: the road of CRISPR/Cas9 from bench to clinic.
    Eid A; Mahfouz MM
    Exp Mol Med; 2016 Oct; 48(10):e265. PubMed ID: 27741224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances and applications of the CRISPR-Cas system in the gene therapy of blood disorders.
    Zanganeh S; Zahedi AM; Sattarzadeh Bardsiri M; Bazi A; Bastanifard M; Shool S; Kouhbananinejad SM; Farsinejad A; Afgar A; Shahabi A; Mirzaei-Parsa MJ
    Gene; 2024 Dec; 931():148865. PubMed ID: 39168259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.